These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27846036)

  • 1. Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.
    Fidler S; Olson AD; Bucher HC; Fox J; Thornhill J; Morrison C; Muga R; Phillips A; Frater J; Porter K
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):126-133. PubMed ID: 27846036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART.
    Fidler S; Olson A; Fox J; Phillips A; Morrison C; Thornhill J; Bucher H; Muga R; Porter K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19820. PubMed ID: 25397564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
    Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
    AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
    Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF
    AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
    Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
    Stöhr W; Fidler S; McClure M; Weber J; Cooper D; Ramjee G; Kaleebu P; Tambussi G; Schechter M; Babiker A; Phillips RE; Porter K; Frater J
    PLoS One; 2013; 8(10):e78287. PubMed ID: 24205183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
    Hamlyn E; Ewings FM; Porter K; Cooper DA; Tambussi G; Schechter M; Pedersen C; Okulicz JF; McClure M; Babiker A; Weber J; Fidler S;
    PLoS One; 2012; 7(8):e43754. PubMed ID: 22952756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
    Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
    HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.
    Sörstedt E; Nilsson S; Blaxhult A; Gisslén M; Flamholc L; Sönnerborg A; Yilmaz A
    BMC Infect Dis; 2016 Jun; 16():305. PubMed ID: 27329293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database.
    Han WM; Broom J; Bopage R; Templeton DJ; Edmiston N; Petoumenos K;
    Trop Med Int Health; 2024 Jan; 29(1):42-56. PubMed ID: 38009461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of HIV 'blips' in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).
    Kanapathipillai R; McManus H; Kamarulzaman A; Lim PL; Templeton DJ; Law M; Woolley I
    PLoS One; 2014; 9(2):e86122. PubMed ID: 24516527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
    Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
    HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.
    Young J; Rickenbach M; Calmy A; Bernasconi E; Staehelin C; Schmid P; Cavassini M; Battegay M; Günthard HF; Bucher HC;
    BMC Infect Dis; 2015 Sep; 15():382. PubMed ID: 26392270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
    Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
    HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
    Elvstam O; Malmborn K; Elén S; Marrone G; García F; Zazzi M; Sönnerborg A; Böhm M; Seguin-Devaux C; Björkman P
    Clin Infect Dis; 2023 Jan; 76(1):25-31. PubMed ID: 36100984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
    Chirouze C; Journot V; Le Moing V; Raffi F; Piroth L; Reigadas S; Cassuto JP; Chêne G; Leport C; Hoen B;
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):204-8. PubMed ID: 25590273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.